2010 may be the year for Healthcare IPOs
The stars may be aligning for healthcare initial public offerings (IPOs) in 2010.
According to a recent Reuters news article, the stars may be aligning for healthcare initial public offerings (IPOs) in 2010. Not only are investors expected to take on more risk as the economic outlook improves, but there is potential for the healthcare bill to provide money to the industry.
While the final version of the new health legislation is not yet known, it is unlikely that it would immediately mean more IPOs. However, its passage could be a taken as a sign of stability that would increase the attractiveness of the sector for investors.
According to the article, the heads of a number of equity capital markets said they expected healthcare to produce more IPOs in 2010.
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
FDA Approves First-Ever Cell Therapy Treatment for Rare Progressive Eye Disease
March 20th 2025Encelto is small, semi-permeable capsule implanted in the eye that contains allogeneic retinal pigment epithelium cells genetically engineered to produce specific therapeutic proteins. It will be available in June 2025.
Read More
